Phase 3 Clinical Trials With Primary Completion Dates in October 2024
This is a list of Phase 3 trials with primary completion dates in October 2024 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| AGIO | Agios Pharmaceuticals, Inc. | 2024-10-01 | Phase 3 | NCT05175105 | A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period |
| ARCT | Arcturus Therapeutics Holdings Inc. | 2024-10-01 | Phase 3 | NCT06279871 | Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults |
| CASBF | CanSino Biologics Inc. | 2024-10-01 | Phase 3 | NCT06226714 | A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds |
| FULC | Fulcrum Therapeutics, Inc. | 2024-10-01 | Phase 3 | NCT05397470 | Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH) |
| IMUX | Immunic, Inc. | 2024-10-01 | Phase 3 | NCT05201638 | Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis |
| MTNB | Matinas BioPharma Holdings, Inc. | 2024-10-01 | Phase 3 | NCT05541107 | Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3 |
| OTLK | Outlook Therapeutics, Inc. | 2024-10-01 | Phase 3 | NCT06190093 | A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects with Neovascular Age-related Macular Degeneration (AMD) |
| SAVA | Cassava Sciences, Inc. | 2024-10-01 | Phase 3 | NCT04994483 | Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease |
| SRRK | Scholar Rock Holding Corporation | 2024-10-01 | Phase 3 | NCT05156320 | Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam |
| VRNA | Verona Pharma plc | 2024-10-01 | Phase 3 | NCT06460493 | Effect of Ensifentrine Treatment on CAT Score |